Altogether, these data suggest that Gal-3 might be a mediator involved in poor outcomes, especially in patients with AKI, and improve the risk stratification compared to Screatadm (i.e., meeting the AKI criteria). This evidence concerns the gene LGALS3 and acute kidney injury.